Do you still think Tilray Brands Inc (NASDAQ:TLRY) is worth a look?

In yesterday’s Wall Street session, Tilray Brands Inc (NASDAQ:TLRY) shares traded at $1.83, down -4.69% from the previous session.

As of this writing, 18 analysts cover Tilray Brands Inc (NASDAQ:TLRY). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $4.25 and a low of $1.90, we find $2.50. Given the previous closing price of $1.92, this indicates a potential upside of 30.21 percent. TLRY stock price is now -21.21% away from the 50-day moving average and -22.38% away from the 200-day moving average. The market capitalization of the company currently stands at $1.34B.

There are 13 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $2.75 as their price target over the next twelve months.

With the price target of $3.90, Bernstein recently initiated with Mkt Perform rating for Tilray Brands Inc (NASDAQ: TLRY).

In other news, Kennedy Brendan, Director sold 350,000 shares of the company’s stock on Nov 07. The stock was sold for $1,322,755 at an average price of $3.78. Upon completion of the transaction, the Director now directly owns 6,224,196 shares in the company, valued at $11.39 million. Insiders disposed of 2,278,333 shares of company stock worth roughly $4.17 million over the past 1 year. A total of 1.36% of the company’s stock is owned by insiders.

Monday morning saw Tilray Brands Inc (NASDAQ: TLRY) opened at $1.9700. During the past 12 months, Tilray Brands Inc has had a low of $1.50 and a high of $5.12. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 1.54, and a quick ratio of 1.11. The fifty day moving average price for TLRY is $2.3224 and a two-hundred day moving average price translates $2.3576 for the stock.

The latest earnings results from Tilray Brands Inc (NASDAQ: TLRY) was released for Aug, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.1, missing analysts’ expectations of -$0.05 by -0.05. This compares to -$0.11 EPS in the same period last year. The net profit margin was -222.89% and return on equity was -36.70% for TLRY. The company reported revenue of $176.95 million for the quarter, compared to $153.21 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.49 percent. For the current quarter, analysts expect TLRY to generate $195.06M in revenue.

Tilray Brands Inc(TLRY) Company Profile

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Related Posts